Biochem Pharma (BCHE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (762)	7/11/2000 1:01:33 PM
From: Jim Oravetz	Read Replies (2) of 783

A new U.N. study announced Friday found that AZT, taken in conjunction with another drug, 3TC (lamivudine), loses much of its effectiveness in protecting breast-fed babies after 18 months, according to the New York Times. The new study, which involved 1,797 people and is the largest ever performed on the transmission of AIDS from mothers to children, followed children who were born to these mothers and found that by 18 months, the initial benefit was completely lost as the infants who had been spared infection at birth later became infected through breast-feeding. At the sixth week of the study, 6.7 percent of the babies born to mothers who took the AZT/3TC combination were infected or had died, compared with 16.4 percent in the group that received no drugs. But the infection and death rates after 18 months were 21.3 percent in the treatment group compared with 26.8 percent in the placebo group SNIP.. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next